Basecamp Wealth Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.07M Sell
7,494
-3,465
-32% -$526K 0.24% 38
2026
Q2
$1.72M Hold
10,959
– – 0.32% 36
2026
Q1
$1.67M Hold
10,959
– – 0.35% 30
2025
Q4
$1.51M Buy
+10,959
New +$1.44M 0.32% 31

Other funds holding NVS

Basecamp Wealth Advisors's NVS Position: Q3 2026 in Review

Basecamp Wealth Advisors reduced its Novartis (NVS) stake by 32% in Q3 2026, selling an estimated $526K and leaving 7,494 shares worth $1.07M. The position accounts for 0.24% of the portfolio, ranked #38.

Basecamp Wealth Advisors first reported a position in NVS in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.72M in Q2 2026. 1,543 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Basecamp Wealth Advisors held 7,494 shares of Novartis worth $1.07M as of Q3 2026.
  • Basecamp Wealth Advisors sold 3,465 Novartis shares in Q3 2026, an estimated $526K.
  • Novartis made up 0.24% of Basecamp Wealth Advisors's portfolio in Q3 2026, its #38 holding.
  • Basecamp Wealth Advisors first reported a position in Novartis in Q4 2025 and has held it in 4 quarters since.
  • Basecamp Wealth Advisors's Novartis position peaked at $1.72M in Q2 2026.
  • 1,543 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.